Affymetrix last week reported a net loss of $1.9 million for the quarter, compared to a loss of $12.7 million for its first quarter of 2003. The loss included a charge of $8.1 million associated with the company’s redemption of a set of 4.75 and 5.0 percent convertible subordinated notes. The company reported research and development expenses of $17 million, compared to $16 million for the same quarter in 2003.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.